Supernus制药 SUPN 深 沪
交易中 09-18 10:04:08 美东时间
45.145
+0.345
+0.77%
华盛通- 最 高45.1751
- 今 开44.64
- 成交量 4.74万股
- 最 低 44.285
- 昨 收 44.80
- 总市值 25.28亿
- 52周最高 46.785
- 市盈率 静 34.20
- 换手率 0.08%
- 52周最低 29.16
- 委 比 98.02%
- 总股本 5598.96万
- 历史最高 61.25
- 量 比 1.44
- 振 幅 1.99%
- 历史最低 4.30
- 每 手 1
- 风险率 4.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Piper Sandler Maintains Neutral on Supernus Pharmaceuticals, Raises Price Target to $40
Piper Sandler analyst David Amsellem maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Neutral and raises the price target from $36 to $40.
08-29 21:18
Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals, Inc. announced that its management will participate in three September investor conferences: the Cantor Global Healthcare Conference on September 3, 2025, in New York; the Wells Fargo Healthcare Conference on September 4, 2025, in Boston; and TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit virtually on September 18, 2025. Investors can arrange meetings by contacting the conference coordinators...
08-27 20:15
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $46
Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $42 to $46.
08-06 22:14
Supernus Pharmaceuticals Raises FY2025 Sales Guidance from $600.000M-$630.000M to $670.000M-$700.000M vs $632.103M Est
Supernus Pharmaceuticals (NASDAQ:SUPN) raises FY2025 sales outlook from $600.000 million-$630.000 million to $670.000 million-$700.000 million vs $632.103 million estimate.
08-06 04:27
Supernus Pharmaceuticals Q2 EPS $0.40 Beats $0.11 Estimate, Sales $180.916M Beat $154.061M Estimate
Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.11 by 273.83 percent. This is a 11.11 percent increase over earnings of $0.36 per
08-06 04:09
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, enhancing its neuropsychiatric portfolio with ZURZUVAE® (zuranolone), the first FDA-approved oral treatment for postpartum depression. The deal diversifies Supernus' revenue base, adds a CNS discovery platform, and is projected to generate up to $200 million in annual cost synergies, becoming accretive in 2026. The acquisition also includes contingent value rights for Sage s...
07-31 12:44
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
Supernus Pharmaceuticals announced the expiration of the Hart-Scott-Rodino Act waiting period for its proposed acquisition of Sage Therapeutics. The $8.50 cash offer plus a contingent value right (CVR) for Sage's shares remains subject to certain conditions. The CVR includes potential payments tied to regulatory milestones and U.S. sales targets for ZURZUVAE, with total potential value up to $3.50 per share. The tender offer expires July 30, 2025...
07-28 12:25
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
Supernus Pharmaceuticals, Inc. announced it will report second-quarter 2025 financial and business results after market close on August 5, 2025. A conference call with CEO Jack Khattar and CFO Tim Dec will follow at 4:30 p.m. ET, with a live webcast available on the company’s Investor Relations website. A replay will be accessible for 60 days.
07-22 20:30
Supernus to acquire depression drugmaker Sage
Supernus Pharmaceuticals (NASDAQ:SUPN) has agreed to acquire depression drugmaker Sage Therapeutics (NASDAQ:SAGE) for a total consideration of up to $795M, or $12 per share, in an all-cash deal, the c...
06-16 19:27
